Moderna and Novavax added to ‘mix and match’ COVID-19 vaccine trial

A major U.K. trial looking at whether COVID-19 vaccines can be safely mixed has been expanded to include shots made by Moderna and Novavax, researchers announced on Wednesday.

The Com-Cov study, led by the University of Oxford, was launched in February to compare the effect of administering a first dose of the AstraZeneca–Oxford AZN, +2.18% AZN, 1.65% vaccine, followed a few weeks later by the vaccine made jointly by drug company Pfizer PFE, +0.13% and biotech BioNTech BNTX, 0.16%, and vice versa.